RAPID™-PsA study showed that certolizumab pegol improved signs and symptoms of psoriatic arthritis in patients with and without prior anti-TNF exposure
UCB announces data on Cimzia® (certolizumab pegol) for patients with moderate to severe rheumatoid arthritis at American College of Rheumatology 2012 Congress
